← FDA DRUG APPROVALS

FDA NDA · NDA021301

LEVOXYL

levothyroxine sodium

Sponsor: KING PHARMS

APPLICATION
NDA021301
TYPE
NDA
ORIGINAL APPROVAL
2001-05-25
LATEST ACTION
2018-12-20
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription, Discontinued

Products

LEVOXYL · ReferencePrescription
LEVOTHYROXINE SODIUM 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET · ORAL
LEVOXYL · ReferencePrescription
LEVOTHYROXINE SODIUM 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET · ORAL
LEVOXYL · ReferencePrescription
LEVOTHYROXINE SODIUM 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET · ORAL
LEVOXYL · ReferencePrescription
LEVOTHYROXINE SODIUM 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET · ORAL
LEVOXYL · ReferencePrescription
LEVOTHYROXINE SODIUM 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET · ORAL
LEVOXYL · ReferencePrescription
LEVOTHYROXINE SODIUM 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET · ORAL
LEVOXYL · ReferencePrescription
LEVOTHYROXINE SODIUM 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET · ORAL
LEVOXYL · ReferencePrescription
LEVOTHYROXINE SODIUM 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET · ORAL
LEVOXYL · ReferenceDiscontinued
LEVOTHYROXINE SODIUM 0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
LEVOXYL · ReferencePrescription
LEVOTHYROXINE SODIUM 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET · ORAL
LEVOXYL · ReferencePrescription
LEVOTHYROXINE SODIUM 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET · ORAL
LEVOXYL · ReferencePrescription
LEVOTHYROXINE SODIUM 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium · TABLET · ORAL

Approval history

2018-12-20Labeling · Supplement 38 · standardLabelAP
2014-11-05Manufacturing (CMC) · Supplement 37 · standardAP
2014-05-06Manufacturing (CMC) · Supplement 35 · standardAP
2012-12-14Manufacturing (CMC) · Supplement 34 · standardAP
2011-03-21Manufacturing (CMC) · Supplement 27LabelAP
2009-09-01Supplement · Supplement 28 · standardReviewAP
2008-07-08Labeling · Supplement 26 · standardLetterAP
2005-03-08Labeling · Supplement 14 · standardLetterAP
2003-07-23Manufacturing (CMC) · Supplement 6 · standardLetterAP
2002-12-31Manufacturing (CMC) · Supplement 3 · standardAP
2002-07-17Labeling · Supplement 2 · standardLetterAP
2002-04-03Manufacturing (CMC) · Supplement 1 · standardAP
2001-05-25Type 5 - New Formulation or New Manufacturer · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →